TG Therapeutics Inc (USD)
TGTX
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range7.63 | 8.38
52-Wk Range3.32 | 9.38
Last Close7.68
Mkt Cap (m)764.63
Dividend yield-
ISINUS88322Q1085
Volume1,758,215
Exchange VenueNAS

Company Profile

TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development & commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

Key Information
Price/Earning-
Price/Book0.00
Price/Sales4249.33
P/CF-
Rev Growth (3 year avg)-0.08
EPS Growth (3 year avg)-
Operating Margin % -114736.84
Net Margin %-114132.89
Return on Equity-381.16
Debt/Equity0.00

Legal Documents

Prospectus
en 05/03/2019
Annual Report
en 31/12/2018

Financials

Income Statement
USD201320142015201620172018
Revenue (m)
Operating Income (m)-20-56-63-79-119-174
Net Income (m)-20-56-63-78-118-173
Basic EPS-0.81-1.64-1.38-1.60-1.91-2.30
Avg. Diluted Shares Outstanding (m)253446496275
Balance Sheet
USD201320142015201620172018
Current Assets (m)428587519379
Non Current Assets (m)6227445
Total Assets (m)4887113559784
Current Liabilities (m)6511172839
Total Liabilities (m)------
Total Equity (m)4080102366724
Cash Flows
USD201320142015201620172018
Operating Cash Flows (m)-11-35-45-62-94-129
Capital Expenditure (m)
Figures are quoted in USD unless stated otherwise
0.00 (0.00%)
$
7.68
Last Price